• FDA grants RMAT designation to SanBio’s cell therapy pharmaceutical-technology
    September 25, 2019
    The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SanBio Group’s cell therapy, SB623, to treat chronic neurological motor deficits secondary ...
PharmaSources Customer Service